All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Grzegorz NowakowskiScientific Advisory Board Member
Professor Grzegorz Nowakowski is an Associate Professor of Medicine and Oncology and a consultant in the Division of Hematology at the Department of Internal Medicine at the Mayo Clinic, Rochester, US. He completed his medical degree at the Medical University of Warsaw, Warsaw, PL, in 1998 following Clerkships in 1996 and 1997 at Mississauga Hospital, Mississauga, CN. Prof. Nowakowski then took up a research fellowship in experimental bone marrow transplantation at the University of Massachusetts Cancer Center, Worcester, US, and completed his residency in Internal Medicine at Yale School of Medicine, New Haven, US. In 2006, he became a fellow as part of the Hematology/Oncology Fellowship Program at the Mayo School of Graduate Medical Education, Mayo Clinic College of Medicine and Science, Rochester, US.
Prof. Grzegorz is mainly focused on the identification of novel prognostic markers in chronic lymphocytic leukemia using phage display peptide libraries, specifically very late antigen-4 (VLA-4), in resistance to chemotherapy and IGH and BCL2 mutations in chronic lymphocytic leukemia. Besides this, he is also studying natural killer cell and large granular lymphocytic leukemias. He has authored or co-authored more than 120 publications in the field and is active in education.
Positions of responsibility/awards:
- High Distinction Graduate Award from the Medical University of Warsaw and Ministry of Health, 1998
- American Society of Hematology (ASH) Merit Award — Best abstract in resident physician category, 2000
- Best Clinical Vignette, awarded by the American College of Physicians, 2001
- President’s award for Scientific Excellence, awarded by the International Society for Preventive Oncology, 2002
- Outstanding Graduate Award at Norwalk Hospital, Yale University School of Medicine, 2002
- Robert A. Kyle Research Award from the Mayo Clinic College of Medicine and Science, 2003
- Merit award from the American Society of Clinical Oncology (ASCO), 2005
- William H.J. Summerskill Award, 2006
- Best Educators for Resident Education award at the Department of Internal Medicine, Mayo Clinic, 2011
- 2012 Teacher of the Year of the Hematology-Oncology Fellows
- Leadership Development Program award from ASCO, 2012